David Braun's Blog

Keeping Strategy in Sight When Pursuing Acquisitions

Deferring to advisors during the M&A process can be detrimental to a company, as evidenced by the back and forth over Valeant Pharmaceuticals’ unsolicited $53 billion bid to acquire Allergan, the maker of Botox. The maneuvering over the past several months has become heated and off-track. Or as the Deal Professor column puts it: “Some

Read more ...
The Dangers of Getting Swept Away In the Excitement of a Deal

“The danger with a mergers-and-acquisitions boom is that chief executives could allow themselves to get carried away by the thrill of the hunt, reducing their focus on internal investment projects that might have a better chance of bearing fruit,” says the New York Time’s Dealbook column. M&A activity has reached record highs and shows no

Read more ...
Staying Connected: 4 Ideas for Meeting with Your Acquisition Team

Team meetings are important in order to move forward confidently when it comes to due diligence.  Ideally I would want everyone on your team to be physically together, but I understand in today’s environment that may be difficult to schedule, and you’ll have to be creative to maintain team cohesion. Here are a few suggestions

Read more ...